Evestra, a biopharmaceutical company, is operating from two facilities located in the San Antonio Texas area. The Schertz 13,000 sq. ft. facility houses the Company headquarters and state-of-the-art commercial facility for producing vaginal ring type products.  The San Antonio facility located at Omicron Drive (7,500 sq.ft.) is dedicated to R&D activities including manufacturing of cGMP, and non-GMP-grade active pharmaceutical ingredients (APIs) for early-stage clinical studies.  Both facilities are equipped with state-of-the-art analytical testing capabilities and equipment in support of analytical development and cGMP manufacturing.  Evestra has a long and successful record of manufacturing kilo scale steroidal APIs for third parties, and its own products throughout the years.  In addition, Evestra is currently developing oral and vaginal ring drug products and has conducted preclinical and Phase I/II clinical studies that have been published.

Our Strategic Approach

The Evestra team continues to build an innovative biopharmaceutical business by pursuing the following strategy:

  • Establish an attractive portfolio of near-term and innovative women’s healthcare products
  • Commercialize its product through strategic collaborations with established pharmaceutical companies
  • Address unmet market needs for longer-term active products through drug delivery approaches such as vaginal rings and injectable products
  • Generating income from partnerships around generic vaginal ring products
  • Fund early-stage drug development via non-diluted grants
  • Placements of equity
  • Pursue innovative R&D in areas of oncology, that especially target women’s health